Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The cell and gene therapy sectors are growing exponentially, with new players emerging daily and much progress being made both in and out of the lab. CGTLive’s Around the Helix is your chance to catch up with the latest news in cell and gene therapies, including partnerships, pipeline updates, and more.
A patient that received a living donor kidney transplant and was treated with FCR001 as part of the phase 3 FREEDOM-1 trial (NCT03995901) has died after being hospitalized with grade 4 graft-vs-host disease complicated by serious infections leading to respiratory and renal failure.
The NIH has awarded a $1.5 million SBIR Direct-to-Phase 2 grant to Nanoscope Therapeutics to support advancement of its Engineered Mechanosensitive Channel glaucoma therapy.
Celyad Oncology is no longer developing its investigational chimeric antigen receptor T-cell therapy CYAD-101 for the treatment of unresectable metastatic colorectal cancer.
A new manufacturing process developed by investigators at University Hospitals Seidman Cancer Center in collaboration with a biotech start-up company could reduce the time to manufacture chimeric antigen receptor T-cell therapies to approximately 24 hours.
The strategic investment is aimed at advancing the development of investigational gene therapies for Rett syndrome and giant axonal neuropathy.
The investigational gene therapy was previously granted FDA fast track designation and FDA and EU orphan drug designations.
The recommendation was informed by data from ALLELE, a phase 3 clinical trial.
The decision was informed by safety and efficacy results from the LUMMICAR STUDY 1, a phase 1/2 clinical trial.
LX1004 previously received FDA orphan drug designation and rare pediatric disease designation.
Via the exclusive license agreement, Kite aims to leverage the platform in the development of new CAR-T therapies.
Applied Genetic Technologies Corporation believes the acquisition will allow for the continued development of AGTC-501, an investigational gene therapy intended for the treatment of X-linked retinitis pigmentosa.
The new research collaboration will explore the potential of combining the University of Pennsylvania’s CAR-T therapies with Candel's viral immunotherapies.